MedPath

NSABP FOUNDATION, INC.

🇺🇸United States
Ownership
Private
Employees
-
Market Cap
-
Website
http://www.foundation.nsabp.org

Clinical Trials

66

Active:3
Completed:38

Trial Phases

4 Phases

Phase 1:4
Phase 2:20
Phase 3:29
+1 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (57 trials with phase data)• Click on a phase to view related trials

Phase 3
29 (50.9%)
Phase 2
20 (35.1%)
Not Applicable
4 (7.0%)
Phase 1
4 (7.0%)

A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)

Not Applicable
Not yet recruiting
Conditions
Colo-rectal Cancer
Interventions
Drug: cemiplimab plus fianlimab
Drug: cemiplimab + REGN7075
Other: ctDNA testing
First Posted Date
2025-07-10
Last Posted Date
2025-07-10
Lead Sponsor
NSABP Foundation Inc
Target Recruit Count
79
Registration Number
NCT07058012

A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy

Phase 2
Withdrawn
Conditions
Colon Cancer
Interventions
Diagnostic Test: Signatera test
First Posted Date
2022-01-05
Last Posted Date
2022-11-04
Lead Sponsor
NSABP Foundation Inc
Registration Number
NCT05178576
Locations
🇺🇸

UF Health Davis Cancer Pavilion and Shands Med Plaza, Gainesville, Florida, United States

🇺🇸

University of Iowa, Iowa City, Iowa, United States

🇺🇸

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

and more 2 locations

Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer

Phase 2
Completed
Conditions
Breast Cancer
Interventions
Diagnostic Test: Oncotype DX Breast Recurrence Score
First Posted Date
2018-08-14
Last Posted Date
2022-04-20
Lead Sponsor
NSABP Foundation Inc
Target Recruit Count
24
Registration Number
NCT03628066
Locations
🇺🇸

Breast Cancer Care Specialist, Fountain Valley, California, United States

🇺🇸

Orange Coast Blood and Cancer Care, Fountain Valley, California, United States

🇺🇸

Saddleback Memorial Medical Center, Laguna Hills, California, United States

and more 12 locations

Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients

Phase 1
Conditions
Metastatic Colorectal Cancer
Interventions
Dietary Supplement: Folic Acid
Dietary Supplement: Vitamin B-12
First Posted Date
2018-08-13
Last Posted Date
2022-06-10
Lead Sponsor
NSABP Foundation Inc
Target Recruit Count
33
Registration Number
NCT03626922
Locations
🇺🇸

UF Health Davis Cancer Pavilion & Shands Medical Plaza, Gainesville, Florida, United States

🇺🇸

Cancer Care Specialists of Central Illinois, Decatur, Illinois, United States

🇺🇸

Decatur Memorial Hospital, Decatur, Illinois, United States

and more 12 locations

Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status

Phase 2
Conditions
Metastatic Colorectal Cancer
Interventions
Diagnostic Test: Guardant360 Diagnostic Test
First Posted Date
2018-03-08
Last Posted Date
2022-03-31
Lead Sponsor
NSABP Foundation Inc
Target Recruit Count
35
Registration Number
NCT03457896
Locations
🇺🇸

Kaiser Permanente-Anaheim, Anaheim, California, United States

🇺🇸

Kaiser Permanente-Baldwin, Baldwin Park, California, United States

🇺🇸

Kaiser Permanente-Bellflower, Bellflower, California, United States

and more 44 locations
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 14
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath